Document is current
Any future updates will be listed below
-
Authors
Placido, Davide https://orcid.org/0000-0002-8327-8838
Yuan, Bo
Hjaltelin, Jessica X.
Zheng, Chunlei https://orcid.org/0000-0002-9737-461X
Haue, Amalie D. https://orcid.org/0000-0001-7656-7976
Chmura, Piotr J. https://orcid.org/0000-0002-9371-6918
Yuan, Chen
Kim, Jihye
Umeton, Renato https://orcid.org/0000-0002-5561-6932
Antell, Gregory
Chowdhury, Alexander
Franz, Alexandra
Brais, Lauren
Andrews, Elizabeth
Marks, Debora S. https://orcid.org/0000-0001-9388-2281
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Ayandeh, Siamack
Brophy, Mary T.
Do, Nhan V. https://orcid.org/0000-0001-6868-7011
Kraft, Peter https://orcid.org/0000-0002-4472-8103
Wolpin, Brian M. https://orcid.org/0000-0002-0455-1032
Rosenthal, Michael H.
Fillmore, Nathanael R.
Brunak, Søren https://orcid.org/0000-0003-0316-5866
Sander, Chris https://orcid.org/0000-0001-6059-6270
-
Funding
Funding for this research was provided by:
EIF | Stand Up To Cancer (SU2C#6180)
U.S. Department of Health & Human Services | National Institutes of Health (U01 CA210171, P50 CA127003, U01 CA210171)
Novo Nordisk Fonden (NNF17OC0027594, NNF14CC0001)
- License Information
-
More Information
Article History
Received: 10 March 2022
Accepted: 31 March 2023
First Online: 8 May 2023
Competing interests
: S.B. has ownership in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S and ALK Abello and has managing board memberships in Proscion A/S and Intomics A/S. B.M.W. notes grant funding from Celgene and Eli Lilly and consulting fees from BioLineRx, Celgene and GRAIL. A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas and was a scientific advisory board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until 31 July 2020. D.S.M. is an advisor for Dyno Therapeutics, Octant, Jura Bio, Tectonic Therapeutic and Genentech and is a co-founder of Seismic Therapeutic. C.S. is on the scientific advisory board of CytoReason. From 1 August 2020, A.R. is an employee of Genentech and has equity in Roche. The remaining authors declare no competing interests.
